Evidence map›Paper›PMID 37762327›Full record

ArticleInternational journal of molecular sciences2023

Dual-Target

Pritika Ramharack, Elliasu Y Salifu, Clement Agoni

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Pritika RamharackBiomedical Research and Innovation Platform (BRIP), South African Medical Research Council (SAMRC), Cape Town 7505, South Africa.
Elliasu Y SalifuBiomedical Research and Innovation Platform (BRIP), South African Medical Research Council (SAMRC), Cape Town 7505, South Africa.ORCID 0000-0001-8713-5001
Clement AgoniDiscipline of Pharmaceutical Sciences, School of Health Sciences, Westville Campus, University of KwaZulu-Natal, Durban 4001, South Africa.ORCID 0000-0001-6130-8031
South African Medical Research Council · ZAUniversity College Dublin · IE

Funding

National Research Foundation 29429
6 · The paper itself

Abstract

The escalating prevalence of drug-resistant strains of

Indexed as

Folic Acid AntagonistsMycobacterium tuberculosisAspartic AcidCatalysisFolic AcidAspartic AcidFolic AcidFolic Acid Antagonistscheminformaticsdual-target modulationmolecular dynamic simulationsMtb drug resistance

Identifiers

PMID37762327
PMCPMC10530724
OpenAlexW4386715382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.